Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer

Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuai, Lu, Lu, Pan, Feng, Yang, Chunsheng, Liang, Jing, Liu, Jinfeng, Wang, Jian, Shen, Rong, Xin, Fu-Ze, Zhang, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110705/
https://www.ncbi.nlm.nih.gov/pubmed/35063062
http://dx.doi.org/10.3727/096504022X16427607626672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110705/
https://www.ncbi.nlm.nih.gov/pubmed/35063062
http://dx.doi.org/10.3727/096504022X16427607626672

Ejemplares similares